Mode
Text Size
Log in / Sign up
N/A Completed N=189,426

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Source: ClinicalTrials.gov NCT02197078 ↗
Enrolled (actual)
189,426
Serious AEs
—
Results posted
Apr 2020
Primary outcomePrimary: Number of Participants With Major Adverse Cardiovascular Event — 165; 151; 120; 102 Participants

Summary

This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The primary analysis will be conducted among patients without prior within-class medication use.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Major Adverse Cardiovascular Event
165; 151; 120; 102; 127; 82 —
PRIMARY
Number of Participants With Coronary Revascularization
82; 81; 67; 54; 67; 46 —
PRIMARY
Number of Participants With Acute Coronary Syndrome
93; 72; 76; 48; 72; 43 —
PRIMARY
Number of Participants With Stroke
42; 42; 30; 30; 37; 16 —
SECONDARY
Number of Participants With Heart Failure Hospitalization
53; 90; 27; 51; 43; 47 —
SECONDARY
Number of Participants With Incident End Stage Renal Disease
49; 75; 28; 48; 38; 43 —
SECONDARY
Number of Participants With Acute Renal Failure
222; 300; 152; 198; 163; 167 —
SECONDARY
Number of Participants With Acute Renal Failure Requiring Dialysis
7; 13; 6; 10; 5; 9 —

Eligibility Criteria

Inclusion criteria

  • A dispensing of an oral hypoglycemic medication
  • A diagnosis of type 2 diabetes mellitus (T2DM)

Exclusion criteria

  • less than 18 years old
  • missing or ambiguous age or sex information
  • at least one diagnosis of type 1 diabetes mellitus
  • less than 6 months enrolment in the database preceding the date of the first dispensing
  • secondary diabetes
  • history of cancer
  • end-stage renal disease (ESRD)
  • HIV
  • organ transplant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02197078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search